QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
QQQ   328.59 (+0.15%)
AAPL   143.16 (+0.17%)
MSFT   232.33 (+1.22%)
FB   282.05 (+1.45%)
GOOGL   1,907.95 (+0.72%)
AMZN   3,326.13 (+0.98%)
TSLA   883.09 (+0.26%)
NVDA   537.41 (-1.60%)
BABA   265.92 (+1.74%)
CGC   35.52 (+7.93%)
GE   11.29 (+2.73%)
MU   79.51 (-2.18%)
AMD   94.71 (+0.62%)
NIO   60.31 (+0.53%)
T   29.75 (+2.20%)
F   11.19 (-0.89%)
ACB   10.67 (+5.02%)
BA   202.06 (-0.64%)
DIS   169.56 (-1.36%)
NFLX   561.93 (+0.92%)
GILD   66.70 (-2.14%)
Log in
NASDAQ:NEOS

Neos Therapeutics Stock Forecast, Price & News

$0.93
+0.05 (+5.66 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.91
Now: $0.93
$1.02
50-Day Range
$0.55
MA: $0.71
$0.90
52-Week Range
$0.45
Now: $0.93
$1.98
Volume10.08 million shs
Average Volume5.92 million shs
Market Capitalization$46.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
Neos Therapeutics logo

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

1162nd out of 1,925 stocks

Pharmaceutical Preparations Industry

536th out of 773 stocks

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Employees213
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.65 million
Book Value($0.12) per share

Profitability

Net Income$-16,900,000.00

Miscellaneous

Market Cap$46.44 million
Next Earnings Date3/12/2021 (Estimated)
OptionableOptionable
$0.93
+0.05 (+5.66 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

How has Neos Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEOS shares have decreased by 32.4% and is now trading at $0.9334.
View which stocks have been most impacted by COVID-19
.

Is Neos Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Neos Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOS, but not buy additional shares or sell existing shares.
View analyst ratings for Neos Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neos Therapeutics?

Wall Street analysts have given Neos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Mark Tengler's approval rating as Neos Therapeutics' CEO?

10 employees have rated Neos Therapeutics CEO Mark Tengler on Glassdoor.com. Mark Tengler has an approval rating of 26% among Neos Therapeutics' employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Neos Therapeutics
.

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter.
View Neos Therapeutics' earnings history
.

Are investors shorting Neos Therapeutics?

Neos Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 1,150,000 shares, a drop of 49.1% from the December 15th total of 2,260,000 shares. Based on an average daily volume of 4,040,000 shares, the short-interest ratio is presently 0.3 days. Currently, 2.4% of the company's stock are short sold.
View Neos Therapeutics' Short Interest
.

Who are some of Neos Therapeutics' key competitors?

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the following people:
  • Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 52, Pay $794.86k)
  • Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 62, Pay $527.12k)
  • Mr. John P. Limongelli, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50, Pay $406.06k)
  • Ms. Margaret Cabano, VP of Operations
  • Mr. Joe Calarco, Chief Compliance Officer
  • Ms. Sarah Foster, VP of HR
  • Mr. Russ McMahen, Sr. VP of R&D

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $0.93.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $46.44 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 213 workers across the globe.

What is Neos Therapeutics' official website?

The official website for Neos Therapeutics is www.neostx.com.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.